GeoVax Labs Spotlighted on Inc. Magazine Website

SMYRNA, Ga., May 20 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVXD), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, is spotlighted on an interactive map posted on the website of Inc. magazine.

The map, created by Nitasha Tiku and April Joyner, is headlined "Incubation Nation: Where Great Ideas Are Born."  Tiku and Joyner write:  "Spun out of university research labs or started by local entrepreneurs trying to supercharge their hometowns, business incubators are everywhere.  This map puts the spotlight on 20 initiatives."  Below this is a map of the U.S. with 20 "business incubator" cities labeled.

When users click on Atlanta, Georgia, a text box pops up that reads:  "The Georgia Research Alliance, a consortium of six universities, fosters collaboration across different campuses and helps commercialize the results.  It has generated more than 150 companies.  Who gets in: Advanced computing, multimedia, biotech, and alternative-energy start-ups. Breakout company:  In March, GeoVax Labs got the nod from the FDA to test its HIV vaccine in human clinical trials."

Robert T. McNally, GeoVax's president and CEO, commented:  "We are pleased that Inc. magazine has chosen to call attention to our HIV vaccine efforts in such a dynamic format.  We are confident that our work is on the right track, and are proud to be chosen by the magazine as the most notable 'breakout company' in the Atlanta area."

To see the interactive map, please visit:

www.inc.com/magazine/20100501/the-best-business-incubators.html

About GeoVax Labs, Inc.

GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV (Human Immunodeficiency Virus – that leads to AIDS) and other infectious agents. Our goals include developing HIV/AIDS vaccines for global markets, manufacturing and testing these vaccines under GMP/GLP conditions (FDA guidelines), conducting clinical trials for vaccine safety and effectiveness, and obtaining regulatory approvals to move the product forward. All preventative Phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA and MVA vaccines have demonstrated the ability to raise anti-HIV immune responses as well as for their safety. Successful results from all Phase 1 testing supported the initiation of the first Phase 2 testing. GeoVax's Phase 2 human trial began in January 2009 and will involve 225 participants at sites in the United States and South America. Recently the FDA granted permission to proceed with a Phase 1 therapeutic trial for individuals infected with HIV. Long term, we expect that GeoVax will grant manufacturing and distribution rights in several global markets in return for upfront fees, collaborative development agreements, and royalties on sales and distribution revenues. Internal vaccine manufacturing and distribution will also be considered by GeoVax. For more information, please visit www.geovax.com.

Forward-Looking Statements

Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.

SOURCE GeoVax Labs, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED